ConductScience.org, home

Paper1663283

In vitro and in vivo activities of sparfloxacin (AT-4140) against Mycobacterium tuberculosis.

Ji B and 2 others. Tubercle, 1991. Cited by 38 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. In vitro and in vivo activities of sparfloxacin (AT-4140) against Mycobacterium tuberculosis. Papers, record 1663283. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/1663283

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
In vitro and in vivo activities of sparfloxacin (AT-4140) against Mycobacterium tuberculosis.
PubMed
Journal
Tubercle
PubMed
Year
1991
PubMed
Publication types
Comparative Study, Journal Article
PubMed
Citations, by iCite
38
iCite
Relative citation ratio, by iCite
1.71
iCite
Revised in PubMed
2019-09-07
PubMed

Authors3

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Ji BB
2Truffot-Pernot CC
3Grosset JJ

Source PubMed

Topics11

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Anti-Infective AgentsMajor topic
FluoroquinolonesMajor topic
Mycobacterium tuberculosisMajor topic
QuinolonesMajor topic
Animals
Dose-Response Relationship, Drug
Female
Mice
Microbial Sensitivity Tests
Ofloxacin
Tuberculosis

Source PubMed

Cited by16

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 38 citations.

PMIDTitleJournalYearIn PapersSource
24,550,337Pharmacokinetics of ofloxacin and levofloxacin for prevention and treatment of multidrug-resistant tuberculosis in children.Antimicrob Agents Chemother2014https://conductscience.org/library/papers/24550337PubMed
11,120,969Activity of moxifloxacin by itself and in combination with ethambutol, rifabutin, and azithromycin in vitro and in vivo against Mycobacterium avium.Antimicrob Agents Chemother2001https://conductscience.org/library/papers/11120969PubMed
10,898,685Antimycobacterial activities of novel levofloxacin analogues.Antimicrob Agents Chemother2000https://conductscience.org/library/papers/10898685PubMed
9,869,570Moxifloxacin (BAY12-8039), a new 8-methoxyquinolone, is active in a mouse model of tuberculosis.Antimicrob Agents Chemother1999https://conductscience.org/library/papers/9869570PubMed
9,687,411Correlation between quinolone susceptibility patterns and sequences in the A and B subunits of DNA gyrase in mycobacteria.Antimicrob Agents Chemother1998https://conductscience.org/library/papers/9687411PubMed
9,687,408In vitro and in vivo activities of moxifloxacin and clinafloxacin against Mycobacterium tuberculosis.Antimicrob Agents Chemother1998https://conductscience.org/library/papers/9687408PubMed
9,559,785Accumulation of norfloxacin by Mycobacterium aurum and Mycobacterium smegmatis.Antimicrob Agents Chemother1998https://conductscience.org/library/papers/9559785PubMed
9,056,001Which aminoglycoside or fluoroquinolone is more active against Mycobacterium tuberculosis in mice?Antimicrob Agents Chemother1997https://conductscience.org/library/papers/9056001PubMed
8,452,346In vitro and in vivo activities of the nitroimidazole CGI 17341 against Mycobacterium tuberculosis.Antimicrob Agents Chemother1993https://conductscience.org/library/papers/8452346PubMed
8,384,811Powerful bactericidal activity of sparfloxacin (AT-4140) against Mycobacterium tuberculosis in mice.Antimicrob Agents Chemother1993https://conductscience.org/library/papers/8384811PubMed
8,285,617Therapy of multidrug-resistant tuberculosis: lessons from studies with mice.Antimicrob Agents Chemother1993https://conductscience.org/library/papers/8285617PubMed
7,979,275Activity of levofloxacin in a murine model of tuberculosis.Antimicrob Agents Chemother1994https://conductscience.org/library/papers/7979275PubMed
7,793,885Comparison of activities of fluoroquinolones in murine macrophages infected with Mycobacterium tuberculosis.Antimicrob Agents Chemother1995https://conductscience.org/library/papers/7793885PubMed
7,741,981Avoidance and management of adverse reactions to antituberculosis drugs.Drug Saf1995https://conductscience.org/library/papers/7741981PubMed
7,574,527In vitro and in vivo activities of levofloxacin against Mycobacterium tuberculosis.Antimicrob Agents Chemother1995https://conductscience.org/library/papers/7574527PubMed
7,486,904Characterization of fluoroquinolone-resistant mutant strains of Mycobacterium tuberculosis selected in the laboratory and isolated from patients.Antimicrob Agents Chemother1995https://conductscience.org/library/papers/7486904PubMed

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/1663283

GET https://conductscience.org/api/papers/v1/1663283/authors